These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 19525899

  • 1. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease.
    McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ.
    J Neuropathol Exp Neurol; 2009 May; 68(5):515-24. PubMed ID: 19525899
    [Abstract] [Full Text] [Related]

  • 2. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.
    Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, Romero-Ramos M.
    Neurobiol Dis; 2013 Aug; 56():47-58. PubMed ID: 23567651
    [Abstract] [Full Text] [Related]

  • 3. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
    Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N.
    Proc Natl Acad Sci U S A; 2008 Jan 15; 105(2):763-8. PubMed ID: 18178617
    [Abstract] [Full Text] [Related]

  • 4. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T.
    J Neurosci; 2011 Nov 16; 31(46):16884-94. PubMed ID: 22090514
    [Abstract] [Full Text] [Related]

  • 5. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A.
    J Neurosci; 2002 Apr 01; 22(7):2780-91. PubMed ID: 11923443
    [Abstract] [Full Text] [Related]

  • 6. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
    Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A.
    Proc Natl Acad Sci U S A; 2003 Mar 04; 100(5):2884-9. PubMed ID: 12601150
    [Abstract] [Full Text] [Related]

  • 7. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.
    Acta Neuropathol Commun; 2017 Feb 01; 5(1):11. PubMed ID: 28143577
    [Abstract] [Full Text] [Related]

  • 8. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S, Fukushima S, Sato H, Sasaki A, Koga K, Koyama S, Kato T.
    PLoS One; 2014 Feb 01; 9(2):e89076. PubMed ID: 24586512
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H.
    J Neurochem; 2004 Oct 01; 91(2):451-61. PubMed ID: 15447678
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.
    Buck K, Landeck N, Ulusoy A, Majbour NK, El-Agnaf OM, Kirik D.
    Neurobiol Dis; 2015 Jun 01; 78():100-14. PubMed ID: 25818009
    [Abstract] [Full Text] [Related]

  • 13. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
    St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ.
    J Neurochem; 2007 Mar 01; 100(6):1449-57. PubMed ID: 17241127
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A.
    Neurobiol Dis; 2012 Mar 01; 45(3):939-53. PubMed ID: 22182688
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z, Ferger B, Feldon J, Büeler H.
    J Neurobiol; 2002 Oct 01; 53(1):1-10. PubMed ID: 12360578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.